A Phase I, open-label, drug-drug interaction study between multiple oral doses of GLPG1972 and a single dose of midazolam in healthy male subjects. - DDI study between GLPG1972 and Midazolam in healthy male subjects.

Galapagos NV0 sites18 target enrollmentTBD

Overview

Phase: N/A
Intervention: Not specified
Conditions: Not specified
Sponsor: Galapagos NV
Enrollment: 18
Status: Completed
Last Updated: 2 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

No summary available.

Registry

who.int

Start Date

TBD

End Date

TBD

Last Updated

2 years ago

Study Type

Interventional

Investigators

Sponsor

Galapagos NV

Eligibility Criteria

Inclusion Criteria

•healthy male volunteers
•18 \- 50 years, inclusive
•BMI 18\.0 \- 30\.0 kg/m2
•weight at least 50 kilograms
•non smokers

Exclusion Criteria

•Suffering from hepatitis B, hepatitis C, cancer or HIV/AIDS. In case of participation in another drug study within 90 days before the start of this study or being a blood donor within 60 days from the start of the study. In case of donating more than 1\.5 liters of blood in the 10 months prior the start of this study. Not allowed is the use of any prescribed medication, over\-the\-counter medication, vitamin preparations and other food supplements, or herbal medications (e.g. St. John\*s Wort), from 14 days prior to the first administration of the study compound until the post\-study visit.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Unknown

Phase 1

Phase 1 Drug-Drug Interaction Study between TAK-272 and Itraconazole, Digoxin and Midazolam

JPRN-jRCT2080222758TAKEDA PHARMACEUTICAL COMPANY LTD.34

Not Yet Recruiting

N/A

A phase 1 study to evaluate drug-drug interactions of Bojungikgitang with Clopidogrel, Atorvastatin, and Fimasartan/Amlodipine in healthy adult volunteers

KCT0007296Kyunghee University-industry Cooperation Foundation42

Not Yet Recruiting

Phase 1

A Phase 1 Drug-Drug Interaction Study to Assess the Interaction Potential of NB-4746 on CYP1A2 and CYP3A4 Substrates in Healthy Volunteers

ACTRN12624001072505ura Bio18

Unknown

Phase 3

An open-label, add-on, drug-drug interaction study to assess the effect of FYX-051 on the pharmacokinetics and safety of warfarin in Japanese healthy adult maleHealthy adult male

JPRN-jRCT2080221293SANWA KAGAKU KENKYUSHO CO.,LTD.12

Active, Not Recruiting

Phase 1

A study in healthy volunteers to discover how the test medicine interacts with other approved medicines1. Non-alcoholic steatohepatitis (NASH)2. Antipsychotic-induced weight gain (AIWG)Not Applicable

ISRCTN10379288Corcept Therapeutics (United States)30